
Currently out of the existing stock ratings of Ryan Deschner, 41 are a BUY (100%).
Analyst Ryan Deschner, currently employed at RAYMOND JAMES, has had 32.25% of price targets met with an average potential upside of 57.8%, reached in 138 days on average.
Ryan Deschner has documented 79 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SPRY, ARS Pharmaceuticals at 06-Nov-2026.
Analyst best performing recommendations are on LQDA (LIQUIDIA TECHNOLOGIES).
The best stock recommendation documented was for LQDA (LIQUIDIA TECHNOLOGIES) on 10/1/2026. The price target of $53 was fulfilled within 41 days with a profit of $25.01 (89.35%), with a performance score of 21.79.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Apr-2023
$9
$6.01 (201.00%)
$19
3 months 4 days ago
(18-Aug-2026)
7/20 (35%)
$5.08 (129.59%)
247
Buy Since 26-Sep-2025
$15
$12.01 (401.67%)
$19
3 months 5 days ago
(17-Aug-2026)
14/24 (58.33%)
$10.94 (269.46%)
437
Buy Since 03-Mar-2016
$11
$8.01 (267.89%)
$14
3 months 12 days ago
(10-Aug-2026)
8/18 (44.44%)
$7 (175.00%)
307
Buy Since 03-May-2024
$10
$7.01 (234.45%)
$10
3 months 15 days ago
(07-Aug-2026)
0/4 (0%)
$6 (150.00%)
Buy Since 04-Mar-2025
$14
$11.01 (368.23%)
$17
3 months 15 days ago
(07-Aug-2026)
0/7 (0%)
$10 (250.00%)
Which stock is Ryan Deschner most bullish on?
Which stock is Ryan Deschner most reserved on?
What Year was the first public recommendation made by Ryan Deschner?